The collaboration integrates Demeetra’s CleanCut CHO platforms and cell line services with NorthX Biologics’ GMP ...
NorthX Biologics and Demeetra today announced a strategic collaboration combining a best-in-class high-titer GS (-/-) CHO ...
NorthX Biologics and Demeetra are collaborating to help biotech companies reach Investigational New Drug and clinical ...
BOSTON & SAN CARLOS, Calif.--(BUSINESS WIRE)--Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced a licensing agreement for its CHO Edge System ...
The MarketWatch News Department was not involved in the creation of this content. SAN DIEGO, Sept. 15, 2025 /PRNewswire/ -- Abzena, the leading end-to-end integrated CDMO for complex biologics and ...
SHANGHAI, Aug. 11, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of WuXia293 Stable ...
This partnership provides the industry with cutting-edge options for mammalian-expressed products. OKLAHOMA CITY & MONTHEY, Switzerland--(BUSINESS WIRE)--ExcellGene SA, a leading Swiss biotech service ...
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Privately held CHO Plus, Inc. announced today a project agreement awarded from the Biomedical Advanced Research and Development Authority ...
TrueSite TI™, the fourth generation of WuXia™ cell line platform, leverages targeted integration technique to streamline clone screening and guarantees expression stability. The platform has achieved ...
U.S. government researchers have made a significant step forward in developing a fully automated process for cell-line development. The National Institute of Allergy and Infectious Diseases (NIAID), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results